News

Pembrolizumab plus physician’s choice of chemotherapy bested placebo plus chemotherapy in improving overall survival rates in patients with HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.

An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.

In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.

Disease-free survival in patients with metastatic breast cancer did not differ between treatment with everolimus or placebo.

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Combining the doxorubicin analogue camsirubicin with pegfilgrastim yielded encouraging clinical activity in patients with advanced soft tissue sarcoma.

Margetuximab did not deliver a significant survival benefit in patients with HER2-positive advanced breast cancer compared with trastuzumab.

Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.

The autologous tumor lysate-loaded dendritic cell vaccination reduced the risk of death for patients with newly diagnosed glioblastoma by 20%.

Ibrutinib demonstrated encouraging responses for patients with relapsed/refractory mantle cell lymphoma in a real-world setting.

The combination of tremelimumab plus durvalumab plus chemotherapy, which was recently approved for patients with non–small cell lung cancer, could represent a new standard of care.

Coadministration CD19- and CD22-directed CAR T-cell therapy produced relatively durable remissions in children with high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia.

A key component of health equity includes ensuring that clinical trials reflect subgroups of patients who are more reflective of real-world populations.

Sotigalimab, a humanized IgG1 monoclonal antibody against human CD40, may hold value in the frontline treatment of patients with metastatic melanoma.

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.

Increasing the duration of bevacizumab treatment did not improve progression-free survival for patients with ovarian cancer.

The 1-year PFS rate among patients with metastatic, triple-negative breast cancer who received a combination eganelisib, atezolizumab, and nab-paclitaxel was 36%.

Patients with non–small cell lung cancer who received toripalimab experienced significant improvements in progression-free survival and overall survival.

In addition to worrying about the staffing needs in oncology units, RNs are facing workplace violence concerns at increasing rates.

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.

Oncology nurses are in a unique position to educate patients with breast cancer about post-mastectomy chest numbness.

The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.

Mirvetuximab soravtansine-gynx, an antibody drug conjugate, has received accelerated approval for platinum-resistant ovarian cancer. The prescribing label comes with warnings for visual toxicities, pneumonitis, and peripheral neuropathy.

Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.

A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.

Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.

During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.